F0U Stock Overview
Researches, develops, manufactures, and commercializes nanotechnology products and materials.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
NAVCO Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.099 |
| 52 Week Low | CA$0.013 |
| Beta | 0 |
| 11 Month Change | -2.00% |
| 3 Month Change | 36.11% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| F0U | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.5% | 0.2% | 0.7% |
| 1Y | n/a | -19.4% | -0.08% |
Return vs Industry: Insufficient data to determine how F0U performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how F0U performed against the German Market.
Price Volatility
| F0U volatility | |
|---|---|
| F0U Average Weekly Movement | 71.9% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: F0U's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine F0U's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Geoffrey Lee | navcopharma.com |
NAVCO Pharmaceuticals Inc. researches, develops, manufactures, and commercializes nanotechnology products and materials. It offers aerosol spray, hand cream and sanitizer, and colloidal silver products. The company also provides COVID PCR testing, PPE, and diagnostic PCR testing, as well as textile and food solutions.
NAVCO Pharmaceuticals Inc. Fundamentals Summary
| F0U fundamental statistics | |
|---|---|
| Market cap | €1.14m |
| Earnings (TTM) | -€1.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs F0U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| F0U income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.68m |
| Earnings | -CA$2.68m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.047 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 309.3% |
How did F0U perform over the long term?
See historical performance and comparison